Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1991-05-28
1992-07-14
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Lymphokine
A61K 3900
Patent
active
051301270
ABSTRACT:
A therapeutic method for treating human tumors in vivo is provided wherein lentinan is administered to the patient followed by treatment with anti-tumor monoclonal antibodies.
REFERENCES:
Herlyn et al. PNAS 79 1982.
Chihara et al. Rev of Immunol & Immuno phar. 1982.
Maed et al.-Gann 64 1973.
Ball et al., Blood, vol. 62, No. 6, 1983, pp. 1203-1210.
Dillman et al., Blood, vol. 59, No. 5, 1982, pp. 1036-1045.
Foon et al., Blood, vol. 64, No. 5, 1984, pp. 1085-1093.
Miller et al., Blood, vol. 58, No. 1, 1981, pp. 78-86.
Miller et al., The Lancet, vol. II, No. 8240, pp. 226-230.
Miller et al., The New Eng. J. Med., vol. 306, No. 9, pp. 517-522.
Nadler et al., Cancer Research, vol. 40, No. 9, pp. 3147-3154.
Ritz et al., Blood, vol. 58, No. 1, 1981, pp. 141-152.
Bell, Journal of Supramolecular Structure, vol. 8, 1979, p. 281, Abstract No. 728. "Monclonal v. Polyclonal Stimulation by B-1355 Polyglucan".
Herlyn, International Journal of Immunopharmacology, vol. 7, 1985, p. 332, Abtract No. 21, "Stimulation of Monoclonal Antibody-Dependent Macrophage-Mediated Cytotoxicity Against Human Tumors by Lentinan".
Herlyn, Biological Abstracts, vol. 80, No. 7, 1985, Abstract No. 60486, "Monoclonal Antibody-Dependent Murine Macrophage-Mediated Cytotoxicity Against Human Tumors is Stimulated by Lentinan".
Herlyn, Japanese Journal of Cancer Research (GANN), vol. 76, pp. 37-42, 1985, "Monoclonal Antibody-Dependent Murine Macrophage-Mediated Cytotoxicity Against Human Tumors is Stimulated by Lentinan".
Dennert et al, "Brief Communication: Antitumor Polysaccharide Lentinan--At Cell Adjuvant," J. Natl. Cancer Institute, vol. 51, No. 5, 1727-1729 (1973).
Maeda et al, "Periodical Consideration on the Establishment of Antitumor Action in Host and Activation of Peritoneal Exudate Cells by Lentinan," Gann, 64, 351-357 (1973).
Herlyn et al, "Inhibition of Growth of Colorectal Carcinoma in Nude Mice by Monoclonal Antibody," Cancer Research 40, 717-721 (1980).
Hamuro et al, "Induction of Cytotoxic Peritoneal Exudate Cells by T-Cell Immune Adjuvants of the .beta.(1.fwdarw.3) Glucan-Type Lentinan and Its Analogues," Immunology, vol. 39, No. 1, 551-559 (1980).
Herlyn et al, "IgG2a Monoclonal Antibodies Inhibit Human Tumor Growth Through Interaction with Effector Cells," Proc. Natl. Acad. Sci. U.S.A. vol. 79, 4761-4765 (1982).
Chihara et al, "Lentinan: Biological Activities and Possible Clinical Use," National Cancer Center Research Institute, Tsukiji, Tokyo and Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan (Estratto dalla rivista EOS No. 3, vol. 11 (1982).
Steplewski et al, "Human Macroph ages Armed with Murine Immunoglobulin G2a Antibodies to Tumors Destroy Human Cancer Cells," Science vol. 211, 865-867 (1983).
Sears et al, "Effects of Monoclonal Antibody Immunotherapy on Patients with Gastrointestinal Adenocarcinoma", J. Biological Response Modifiers, vol. 3, No. 2, 138-150 (1984).
Draper Garnette D.
The Wistar Institute
LandOfFree
Human tumor therapy using beta (1-3) glucanlentinan and anti-tum does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human tumor therapy using beta (1-3) glucanlentinan and anti-tum, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human tumor therapy using beta (1-3) glucanlentinan and anti-tum will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-333478